NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference
Calabasas, CA – July 23, 2025 – (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers,…
NeOnc’s Executive Chairman To Be Featured In Live Interview
Calabasas, CA – July 24, 2025 – (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, is…
NeOnc Executes Sub-License Agreement With Quazar Investment
NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its…
NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership
Calabasas, CA – July 9, 2025 – (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers,…
NeOnc Technologies Holdings, Inc. Joins Russel Microcap® Index
Calabasas, CA – July 9, 2025 – (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers…
NeOnc Signs $50 Million Strategic Term Sheet With Quazar Investment
Calabasas, CA – July 8, 2025 – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has…
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
Calabasas, CA – April 15, 2025 – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its…
NeOnc Expects Full Enrollment In Phase 2a Trial of NEO100-01
CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today…
NeOnc Executive Chairman Assumes Expanded Leadership Role
CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders,…
NeOnc Nears Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today…
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100
Westlake Village, CA – March 31, 2025 – NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical biotechnology company, today announced that the U.S. Food and Drug Administration…
NeOnc Technologies Partners with CBCC Global Research for Clinical Trials on NEO100-01
Westlake Village, CA – March 27, 2025 – NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical biotechnology company, today announced a strategic partnership with CBCC Global Research…
NeOnc Technologies Holdings Announces SEC S-1 Registration For Anticipated On NASDAQ
NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market — Anticipated Listing March 26, Nasdaq Global Market: Symbol NTHI —…
NeOnc Technologies Holdings, Inc. Appoints Dr. Victoria Medvec to Board of Directors
— Dr. Medvec adds extensive knowledge of high-stakes issues including mergers and acquisitions and partnerships to the NeOnc team — Westlake Village, California – March 25, 2025 – NeOnc…
NeOnc Technologies Appointments Dr. Steven L. Giannotta to its Board of Directors
— Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team — Westlake Village, CA – March 25, 2025 – NeOnc Technologies Holdings, Inc.…
NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors
— Delshad adds broad management and financial expertise to the NeOnc team — Westlake Village, California – March 25, 2025 – NeOnc Technologies Holdings, Inc. (to be listed on the…
NeOnc Technologies Holdings, Inc. Appoints Dr. Alan Chiang to Board of Directors
— Dr. Chaing Expands NeOnc’s Expertise in Neurosurgery and Biotechnology — Westlake Village, California – March 25, 2025 – NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global…
NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors
Westlake Village, California – March 25, 2025 – NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, announced…